Drug profile

The FDA adverse-event record for Flumethrin/Imidacloprid

15 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Flumethrin/Imidacloprid. See the species affected, top reactions, and outcomes below.

15
adverse-event reports
0.0%
death-coded share
Dog
most-reported species
9
Lack of efficacy (ectoparasite) - flea - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
15
Total Reports
0
Deaths Reported
0.0%
Death Rate

Active Ingredients

Flumethrin/Imidacloprid

Administration Routes

Topical

Species Affected

Dog 9
Cat 6

Most Affected Breeds

Ragdoll 3
Pointing Dog - German Short-haired 2
Domestic Shorthair 2
Boxer (German Boxer) 1
Crossbred Canine/dog 1
Retriever - Labrador 1
Spaniel - Cocker American 1
Beagle 1
Bichon Frise 1
Domestic Longhair 1

Most Reported Reactions

Lack of efficacy (ectoparasite) - flea 9
Vomiting 3
Lack of efficacy - NOS 2
Lethargy (see also Central nervous system depression in 'Neurological') 2
Intestinal disorder NOS 2
Gagging 1
Polydipsia 1
Recumbency 1
Polyuria 1
Cough 1
Proprioception abnormality 1
Respiratory tract disorder NOS 1

Outcome Breakdown

Outcome Unknown
7 (46.7%)
Ongoing
6 (40.0%)
Recovered/Normal
2 (13.3%)

Flumethrin/Imidacloprid Adverse Event Insights

15 reports name Flumethrin/Imidacloprid; 0 recorded a death outcome (0.0% of reported events, not a population-level mortality rate). Active ingredient: Flumethrin/Imidacloprid. Administration route: Topical.

By species: Dog (9 reports), Cat (6 reports). By breed: Ragdoll (3), Pointing Dog - German Short-haired (2), Domestic Shorthair (2).

Leading clinical signs: Lack of efficacy (ectoparasite) - flea (9), Vomiting (3), Lack of efficacy - NOS (2), Lethargy (see also Central nervous system depression in 'Neurological') (2). Outcome, 15 coded reports: Outcome Unknown leads at 46.7%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.